Blue Stream Laboratories Expands Its Antibody-Drug Conjugates Capabilities

WOBURN, MA--(Marketwired - October 14, 2015) -

Blue Stream Laboratories, an advanced analytical laboratory specializing in recombinant glycoprotein and complex biologics characterization services, is expanding its antibody-drug conjugates (ADC) and is exhibiting at Booth #18 at the World ADC 2015, the definitive forum for sharing new ADC insights, data and research. World ADC takes place Oct. 19-22 at the San Diego Sheraton.

ADCs are a growing class of drugs that use high-targeting antibodies to deliver potent anti-cancer drugs. Because they are highly targeted, ADCs can target and deliver higher doses to specific tumor markers while eliminating side effects common with chemotherapy.

“The ADC field is expanding and, thus, generating a lot of interest and opportunities. By increasing our ADC capabilities, Blue Stream is building on nearly a decade’s worth of experience in the characterization of recombinant protein therapeutics including dozens of projects across many biologic drug conjugates,” said Mario DiPaola, Ph.D., Chief Scientific Officer of Blue Stream Laboratories.

Blue Stream has been working with ADCs for many years. Its analytical and characterization services support the leading developers in the ADC therapeutics industry. Blue Stream is experienced with some of the most widely used ADC linker technologies, as well as a variety of antibody carriers and payloads. Blue Stream offers a complete set of analytical solutions for ADC development and testing. Blue Stream now provides drug-antibody ratio (DAR) determination; Anti-Drug antibody (ADA) testing services; site conjugation/occupancy characterization via mass spectrometry; analysis of free drug and naked antibody; confirmation of secondary structure and aggregation (HOS); extensive method development and ICH validation capabilities; methods for quantifying drug components of ADCs in support of PK and PD studies; and cGMP lot release along with cGMP stability testing.

Last year, the company announced more than a 60 percent increase in revenue in 2014 over 2013, along with a 30 percent expansion of its research and development capabilities. This growth was partially driven by the growth of Blue Stream’s ADC and biosimilars services.

“We continue to emphasize making improvements to our unmatched expertise, methods, quality, and personnel,” DiPaola said.

About Blue Stream Laboratories
Blue Stream Laboratories is an advanced analytical laboratory specializing in recombinant glycoprotein and complex biologics characterization services. Blue Stream supports Pre-IND through cGMP clinical phase product development programs for product characterization, cGMP lot release, and stability program support. Located 10 miles outside of Boston, and serving companies throughout the U.S. and overseas, Blue Stream’s clients range from small start-ups and virtual biotechs to Fortune 500 pharmaceutical and medical device companies. For more information, please visit the company website at www.bluestreamlabs.com.